NasdaqGS - Nasdaq Real Time Price USD

Moderna, Inc. (MRNA)

122.69 +0.80 (+0.66%)
At close: May 9 at 4:00 PM EDT
122.92 +0.23 (+0.19%)
After hours: May 9 at 7:57 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
5,083,000.00
6,754,000.00
18,875,000.00
17,736,000.00
274,000.00
Cost of Revenue
3,997,000.00
4,693,000.00
5,416,000.00
2,617,000.00
8,000.00
Gross Profit
1,086,000.00
2,061,000.00
13,459,000.00
15,119,000.00
266,000.00
Operating Expense
6,225,000.00
6,300,000.00
4,039,000.00
1,823,000.00
1,029,000.00
Operating Income
-5,139,000.00
-4,239,000.00
9,420,000.00
13,296,000.00
-763,000.00
Net Non Operating Interest Income Expense
397,000.00
383,000.00
171,000.00
18,000.00
25,000.00
Other Income Expense
-60,000.00
-86,000.00
-16,000.00
-29,000.00
-6,000.00
Pretax Income
-4,802,000.00
-3,942,000.00
9,575,000.00
13,285,000.00
-744,000.00
Tax Provision
1,166,000.00
772,000.00
1,213,000.00
1,083,000.00
3,000.00
Net Income Common Stockholders
-5,968,000.00
-4,714,000.00
8,362,000.00
12,202,000.00
-747,000.00
Diluted NI Available to Com Stockholders
-5,968,000.00
-4,714,000.00
8,362,000.00
12,202,000.00
-747,000.00
Basic EPS
-15.60
-12.33
21.26
30.31
-1.96
Diluted EPS
-15.60
-12.33
20.12
28.29
-1.96
Basic Average Shares
381,000.00
382,000.00
394,000.00
403,000.00
381,333.06
Diluted Average Shares
381,000.00
382,000.00
416,000.00
431,000.00
381,333.06
Total Operating Income as Reported
-5,139,000.00
-4,239,000.00
9,420,000.00
13,296,000.00
-763,000.00
Total Expenses
10,222,000.00
10,993,000.00
9,455,000.00
4,440,000.00
1,037,000.00
Net Income from Continuing & Discontinued Operation
-5,968,000.00
-4,714,000.00
8,362,000.00
12,202,000.00
-747,000.00
Normalized Income
-5,936,800.00
-4,657,120.00
8,379,460.00
12,202,000.00
-747,000.00
Interest Income
432,000.00
421,000.00
200,000.00
18,000.00
25,000.00
Interest Expense
35,000.00
38,000.00
29,000.00
18,000.00
9,886.00
Net Interest Income
397,000.00
383,000.00
171,000.00
18,000.00
25,000.00
EBIT
-4,767,000.00
-3,904,000.00
9,604,000.00
13,296,000.00
-763,000.00
EBITDA
-4,188,000.00
-3,283,000.00
9,952,000.00
13,528,000.00
-732,000.00
Reconciled Cost of Revenue
3,997,000.00
4,693,000.00
5,416,000.00
2,617,000.00
8,000.00
Reconciled Depreciation
579,000.00
621,000.00
348,000.00
232,000.00
31,000.00
Net Income from Continuing Operation Net Minority Interest
-5,968,000.00
-4,714,000.00
8,362,000.00
12,202,000.00
-747,000.00
Total Unusual Items Excluding Goodwill
-52,000.00
-72,000.00
-20,000.00
1,000.00
1,301.00
Total Unusual Items
-52,000.00
-72,000.00
-20,000.00
1,000.00
1,301.00
Normalized EBITDA
-4,136,000.00
-3,211,000.00
9,972,000.00
13,528,000.00
-732,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-20,800.00
-15,120.00
-2,540.00
--
--
12/31/2020 - 12/7/2018

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

NVO Novo Nordisk A/S
128.66
+1.55%
 
BNTX BioNTech SE
92.06
+2.14%
 
NVAX Novavax, Inc.
4.4700
0.00%
 
VRTX Vertex Pharmaceuticals Incorporated
418.99
+0.04%
 
REGN Regeneron Pharmaceuticals, Inc.
968.00
+1.28%
 
CRSP CRISPR Therapeutics AG
53.55
+0.49%
 
VKTX Viking Therapeutics, Inc.
80.20
+0.36%
 
SAVA Cassava Sciences, Inc.
21.11
-2.13%
 
IBRX ImmunityBio, Inc.
8.06
+1.77%
 
ARDX Ardelyx, Inc.
8.06
-4.95%